Ligand Pharmaceuticals Incorporated Business Finance Contracts & Agreements

Purchase and Sale Agreement, dated May 6, 2024, byand among Ligand Pharmaceuticals Incorporated,Agenus Inc., Agenus Royalty Fund, LLC, and AgenusHoldings 2024, LLC (Filed With SEC on August 7, 2024)

First Amendment to Credit Agreement, dated as of July 8, 2024, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank,... (Filed With SEC on August 7, 2024)

Director Compensation and Stock Ownership Policy, as amended and restated effective August 4, 2023 (Filed With SEC on August 9, 2023)

Director Compensation and Stock Ownership Policy, as amended and restated effective April 19, 2023 (Filed With SEC on May 8, 2023)

Director Compensation and Stock Ownership Policy, as amended and restated, effective April 13, 2020 (Filed With SEC on February 28, 2023)

Form of Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Stock Option Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Contingent Value Rights Agreement, dated as of September 30, 2020, by and between Ligand Pharmaceuticals Incorporated and American Stock Transfer & Trust Company, LLC (Filed With SEC on November 6, 2020)

Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among the Registrant, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera... (Filed With SEC on May 8, 2020)

Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019 (Filed With SEC on February 27, 2020)

Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Finance Trust (Filed With SEC on March 5, 2019)

Supplemental Indenture, dated as of February 20, 2018, between the Company and Wilmington Trust, National Association, as trustee (Filed With SEC on July 30, 2018)

Letter Agreement, dated as of May 18, 2018, between Goldman Sachs & Co. LLC and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

LIGAND PHARMACEUTICALS INCORPORATED AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 22, 2018 0.75% Convertible Senior Notes due 2023 TABLE OF... (Filed With SEC on May 22, 2018)

Third Amendment to Loan and Security Agreement (Filed With SEC on May 9, 2017)

LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective March [ ], 2014) I. DIRECTOR COMPENSATION (Filed With SEC on November 14, 2016)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on May 9, 2016)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on May 9, 2016)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 5, 2015)

LIGANDPHARMACEUTICALS INCORPORATED AS ISSUER 0.75% CONVERTIBLE SENIOR NOTES DUE 2019 INDENTURE DATED AS OF AUGUST 18, 2014 WILMINGTON TRUST, NATIONAL ASSOCIATION AS TRUSTEE TABLE... (Filed With SEC on August 18, 2014)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 5, 2014)

LIGAND PHARMACEUTICALS INCORPORATED NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on February 24, 2014)

LIGAND PHARMACEUTICALS INCORPORATED DOCS ATM financing facility $24,000,000 of Common Stock, $0.001 par value SALES AGREEMENT October 11, 2013 (Filed With SEC on October 16, 2013)

LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) At the Market Issuance Sales Agreement (Filed With SEC on October 16, 2013)

ROYALTY STREAM AND MILESTONE PAYMENTS PURCHASE AGREEMENT (Filed With SEC on August 1, 2013)

SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 25, 2013)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 4, 2012)

LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 26, 2012)

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 23, 2012)

JOINDER AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 23, 2012)

SECURED PROMISSORY NOTE (Filed With SEC on January 26, 2012)

Category

Industry

Companies

Contracts

Ligand Pharmaceuticals Incorporated Business Finance Contracts & Agreements